Home > Journals > European Journal of Physical and Rehabilitation Medicine > Past Issues > European Journal of Physical and Rehabilitation Medicine 2017 December;53(6) > European Journal of Physical and Rehabilitation Medicine 2017 December;53(6):991-7

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE

A Journal on Physical Medicine and Rehabilitation after Pathological Events


Official Journal of the Italian Society of Physical and Rehabilitation Medicine (SIMFER), European Society of Physical and Rehabilitation Medicine (ESPRM), European Union of Medical Specialists - Physical and Rehabilitation Medicine Section (UEMS-PRM), Mediterranean Forum of Physical and Rehabilitation Medicine (MFPRM), Hellenic Society of Physical and Rehabilitation Medicine (EEFIAP)
In association with International Society of Physical and Rehabilitation Medicine (ISPRM)
Indexed/Abstracted in: CINAHL, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,827


eTOC

 

SPECIAL ARTICLE  MANAGEMENT OF NEUROGENIC LOWER URINARY TRACT DYSFUNCTIONFREEfree


European Journal of Physical and Rehabilitation Medicine 2017 December;53(6):991-7

DOI: 10.23736/S1973-9087.17.04978-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity

Charles JOUSSAIN 1, 2 , Véronique PHÉ 3, Alexia EVEN 2, Emmanuel CHARTIER-KASTLER 3, Pierre DENYS 1, 2

1 Medical School Paris Île-de-France Ouest, Inserm U1179, Versailles Saint-Quentin University, Versailles, France; 2 Department of Physical Medicine and Rehabilitation, Raymond-Poincaré AP-HP Hospital, Garches, France; 3 Department of Urology, Pitié-Salpêtrière Academic Hospital, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Paris, France


PDF  


Intradetrusor injection of botulinum toxin A and sacral neuromodulation are the two recommended third line treatments for patients with neurogenic detrusor overactivity, before undergoing with surgery. However, only Botox® injection is supported by a high level of evidence allowing its recommendation by all institutional guidelines. Despite few positive results, sacral neuromodulation should be proposed in carefully selected patients. Indeed, other studies remain mandatory to increase its level of evidence necessary for allowing its use in neurogenic detrusor overactivity.


KEY WORDS: Urinary incontinence - Botulinum toxins, type A - Injections

top of page

Publication History

Issue published online: December 12, 2017
Article first published online: October 25, 2017
Manuscript accepted: October 25, 2017
Manuscript received: September 7, 2017

Cite this article as

Joussain C, Phé V, Even A, Chartier-Kastler E, Denys P. Intradetrusor injection of botulinum toxin A and sacral neuromodulation for neurogenic detrusor overactivity. Eur J Phys Rehabil Med 2017;53:991-7. DOI: 10.23736/S1973-9087.17.04978-4

Corresponding author e-mail

Charles.jsn@free.fr